Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

The Growing Link Between Cancer and Alzheimer’s Disease

August 1, 2019
By Christina Bennett, MS
Article

People with cancer had a slower rate of memory decline both before and after diagnosis, compared with people who were cancer-free, according to the results of a population-based cohort study recently reported in JAMA Network Open. Previous research has shown an inverse association between developing cancer and Alzheimer’s disease, and this study provides further support for this relationship.

The study cohort was made up of 14,583 adults from the Health and Retirement Study who were born before 1949 and had no diagnosis of cancer by 1998. Participants were followed from 1998 to 2014, and during those 16 years, a total of 12,333 participants remained cancer-free and 2,250 developed cancer.

A survey was conducted in 1998 to set a baseline; during the follow-up period, telephone or in-person biennial interviews were conducted to gather additional information, such as whether a participant had been diagnosed with cancer. Proxy interviews were permitted for adults who were too impaired to answer by themselves.

Memory function was assessed throughout follow-up. To assess memory function, participants were asked to recall a 10-word list both immediately and after a delayed period of time. For participants who were too impaired, a proxy was asked to evaluate the individual’s memory according to a 5-item Likert scale and complete the 16-item Informant Questionnaire for Cognitive Decline.

“This is a very important contribution to the literature,” Jane Driver, MD, Division of Aging, Brigham and Women’s Hospital, told Cancer Network.  “[The study] provides a level of evidence that’s stronger than a lot of prior studies, which were really only able to look at overall associations using diagnoses. Here, we actually have a diagnostic test that’s actually measuring cognition and its change over time.”

The study revealed that before a cancer diagnosis was made, participants had a 10.5% (95% CI, 6.2%–14.9%) slower rate of memory decline compared with participants who remained cancer free. After a new cancer diagnosis, the memory appeared to decline but this effect was transient. After a cancer diagnosis, cancer survivors had a 3.9% (95% CI, 0.9%–6.9%) slower rate of memory decline compared with cancer-free individuals. 

Driver said this is a population-based study and the authors were able to look at large numbers of patients, which is “really necessary” to try to answer the question of whether cancer and Alzheimer’s disease were inversely related. In addition, she applauded the study authors’ use of cognitive assessments over time.

“Both before and after the cancer diagnosis, overall, people who develop cancer seem to develop cognitive impairment more slowly than the comparison subjects,” said Driver. “That does really suggest that there’s something to this inverse association, and that maybe it’s not all due to some kind of a bias, which many people have attributed this relationship to over the years.”
About the inclusion of proxy assessments, Driver was not particularly critical, explaining that it’s “to be expected” that as people age and their cognition gets worse, they’re going to need a proxy to provide the information.

“The take home [message] is that it’s worth pursuing the underlying biological explanations for this because although there’s many treatments for cancer, we don’t yet have one effective treatment for Alzheimer’s disease,” said Driver. “I think that many of us are hoping that further investigation of this strange association would perhaps lead us closer to a treatment for Alzheimer’s or at least understanding it better than we have so far.”

 

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Advertisement

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Chris Ryan
October 17th 2025
Article

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Kristi Rosa
October 17th 2025
Article

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.


Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Abemaciclib Regimen Improves Survival in HR+/HER2– Early Breast Cancer

Ashling Wahner
October 17th 2025
Article

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Related Content
Advertisement

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Chris Ryan
October 17th 2025
Article

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Kristi Rosa
October 17th 2025
Article

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.


Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Abemaciclib Regimen Improves Survival in HR+/HER2– Early Breast Cancer

Ashling Wahner
October 17th 2025
Article

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.